Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1

J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7

Contributing Authors: S Ferrari P Ruggieri G Cefalo A Tamburini R Capanna F Fagioli A Comandone R Bertulli G Bisogno E Palmerini M Alberghini A Parafioriti A Linari P Picci G Bacci

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

246 patients with nonmetastatic osteosarcoma were randomized to evaluate the addition of ifosfamide to a primary chemotherapy regimen of methotrexate, cisplatin, and doxorubicin, with patients allocated to chemotherapy with or without ifosfamide. After a median follow-up of 76 months, there was no difference between groups in overall survival, event-free survival, and the percentage of patients wi...